Top-News

BiondVax Pharmaceuticals Ltd News

Keine aktuellen Kursdaten verfügbar
ISIN: IL0011052045
Typ: Aktie

BiondVax Pharmaceuticals Ltd News

26.08.22 - PR Newswire
BIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT
BIOVAXYS CLOSES FIRST TRANCHE OF NON-​BROKERED PRIVATE PLACEMENT PR Newswire
10.08.22 - PR Newswire
BIOVAXYS KÜNDIGT OPTIONSSCHEINVERLÄNGERUNG AN
BIOVAXYS KÜNDIGT OPTIONSSCHEINVERLÄNGERUNG AN PR Newswire
09.08.22 - PR Newswire
BIOVAXYS ANNOUNCES WARRANT EXTENSION
BIOVAXYS ANNOUNCES WARRANT EXTENSION PR Newswire
02.08.22 - PR Newswire
BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT
BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT PR Newswire
04.07.22 - PR Newswire
BIOVAXYS ANNOUNCES PROPOSED DEBT SETTLEMENT
BIOVAXYS ANNOUNCES PROPOSED DEBT SETTLEMENT PR Newswire
15.06.22 - PR Newswire
Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development
Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development PR Newswire
15.06.22 - PR Newswire
Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development
Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development PR Newswire
08.06.22 - PR Newswire
Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study
Bio-​Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study PR Newswire
08.06.22 - PR Newswire
Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study
Bio-​Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study PR Newswire
03.06.22 - PR Newswire
BioVaxys and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research Program
BioVaxys and The Ohio State University Progress Pan-​Sarbecovirus Vaccine Research Program PR Newswire
03.06.22 - PR Newswire
BioVaxys and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research Program
BioVaxys and The Ohio State University Progress Pan-​Sarbecovirus Vaccine Research Program PR Newswire
19.05.22 - PR Newswire
BioVaxys gibt Standort und Hauptprüfer für die erste klinische Studie seines Impfstoffs gegen Eierstockkrebs bekannt und schließt eine zweite Vereinbarung zur Bereitstellung von Tumorzellen ab
BioVaxys gibt Standort und Hauptprüfer für die erste klinische Studie seines Impfstoffs gegen Eierstockkrebs bekannt und schließt eine zweite Vereinbarung zur Bereitstellung von ...
18.05.22 - PR Newswire
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement PR Newswire
18.05.22 - PR Newswire
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement PR Newswire
02.05.22 - PR Newswire
International Patent Application Filed for Cervical Cancer Vaccine
International Patent Application Filed for Cervical Cancer Vaccine PR Newswire
02.05.22 - PR Newswire
Impfstoff gegen Gebärmutterhalskrebs
Impfstoff gegen Gebärmutterhalskrebs PR Newswire
29.04.22 - PR Newswire
BIOVAXYS ANNOUNCES APPOINTMENT TO BOARD OF DIRECTORS
BIOVAXYS ANNOUNCES APPOINTMENT TO BOARD OF DIRECTORS PR Newswire
25.04.22 - PR Newswire
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction PR Newswire
31.03.22 - PR Newswire
BioVaxys erweitert Krebsimpfstoff-Plattform
BioVaxys erweitert Krebsimpfstoff-​Plattform PR Newswire
30.03.22 - PR Newswire
BioVaxys Expands Cancer Vaccine Platform
BioVaxys Expands Cancer Vaccine Platform PR Newswire

Newssuche

Videos

newspaper
18.04.24
Technical Trading: Gold mit weiterem Potenzial
Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »